ORGANIC COMPOUNDS Russian patent published in 2019 - IPC C07D487/04 A61K31/519 A61P25/28 A61P9/10 A61P25/24 A61P29/00 A61P25/18 

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound of formula I possessing PDE2 inhibitor properties. In formula I

(i) R₁ and R₂ together with a nitrogen atom form azetidin-1-yl; (ii) R₃ is H or C_1-4alkyl; (iii) R₄ is phenyl, optionally substituted with one or more groups selected from C_1-4alkyl, C_1-4alkoxy and halogen C_1-4alkyl; (iv) R₆ is H or C_1-4alkyl. Compound can be in free form or in form of a pharmaceutically acceptable salt. Preferred compounds are compounds selected from group comprising 7-(azetidin-1-yl)-3-methyl-1-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidine; 7-(azetidin-1-yl)-1-(5-(4-methoxy-2-methylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidine; 7-(azetidin-1-yl)-1-(5-(4-cyclopropylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidine; 7-(azetidin-1-yl)-1-(5-(4-ethylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidine.

EFFECT: compound can be used in treating a disease, disorder or condition mediated PDE2, such as anxiety, depression, autism spectrum disorder, schizophrenia, anxiety and/or depression in autistic and/or schizophrenic patients, and cognitive disorders associated with schizophrenia or dementia, and so forth.

10 cl, 1 dwg, 8 ex